This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nextgen Healthcare (NXGN) Reports Next Week: What Awaits?
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: NextGen Healthcare (NXGN)
by Zacks Equity Research
NextGen Healthcare (NXGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Bowen Center Expands Access to Care via NextGen's (NXGN) Platform
by Zacks Equity Research
NextGen's (NXGN) platform is likely to expand care to the underserved patient pool by improving the access to and delivery of whole-person care.
Nextgen Healthcare (NXGN) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nextgen Healthcare (NXGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Digital Health Momentum is Here to Stay: 3 MedTech Stocks in Focus
by Trina Mukherjee
Here we look at three stocks, MDRX, CERN and RMD, that investors can keep a watch on the back of their robust digital health prospects.
NextGen (NXGN) Partners With Palmetto to Boost Patient Experience
by Zacks Equity Research
NextGen (NXGN) collaborates with Palmetto to enhance patient experience, through the latter's adoption of NextGen RCM Services.
3 Stocks With Telehealth Offerings for Post-Pandemic Gains
by Riya Anand
Stocks like CVS Health (CVS), Walgreens Boots Alliance (WBA) and Allscripts (MDRX) are expected to continue to grow post-pandemic on a series of remote health care product and service launches.
NextGen (NXGN) Announces Positive Telehealth Survey Results
by Zacks Equity Research
NextGen's (NXGN) recent survey indicates growing preference for telehealth services.
Nextgen Healthcare (NXGN) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 10.53% and 3.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
NextGen (NXGN) Implements API to Aid COVID-19 Vaccination
by Zacks Equity Research
NextGen's (NXGN) API is expected to address the unique and evolving reporting needs of various states as they administer the COVID-19 vaccine.
Analysts Estimate Nextgen Healthcare (NXGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nextgen Healthcare (NXGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NXGN vs. OMCL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NXGN vs. OMCL: Which Stock Is the Better Value Option?
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Allscripts' (MDRX) Sunrise Platform Picked by Mercy Iowa City
by Zacks Equity Research
Allscripts' (MDRX) Sunrise platform gets selected by Mercy Iowa City, thereby enabling the former to help in delivering better patient outcomes and accelerating the future of healthcare.
Here's Why You Should Hold NextGen (NXGN) in Your Portfolio Now
by Zacks Equity Research
Investor optimism is high on NextGen (NXGN) stock, courtesy of its solid prospects.
Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.
Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows
by Zacks Equity Research
Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.
Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.
Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline
by Zacks Equity Research
Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.
Haemonetics (HAE) Q3 Earnings Top Estimates, Margin Contracts
by Zacks Equity Research
Haemonetics (HAE) third-quarter fiscal 2021 revenues declined 7.2% year over year to $240.4 million, improving 14.7% sequentially.
Onmicell (OMCL) Q4 Earnings Beat Estimates, Margin Contracts
by Zacks Equity Research
Omnicell's (OMCL) fourth-quarter 2020 revenues rose 0.36% year over year to $249.2 million, improving 16.1% sequentially.
NextGen Healthcare (NXGN) Loses 8.8% Despite Q3 Earnings Beat
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strong segmental performance.
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
by Zacks Equity Research
Zacks Industry Outlook Highlights: Omnicell, NextGen Healthcare, NantHealth, Allscripts Healthcare Solutions and Quest Diagnostics
Accuray (ARAY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) registers growth in Service revenues during fiscal Q2.
Stryker (SYK) Q4 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Stryker's (SYK) fourth-quarter earnings reflect strong segmental performance.